Cronos Group Inc. (CRON) Stock: Price, Forecast & Analyst Target

Cronos Group Inc. Company Overview

Cronos Group Inc. operates in the cannabinoid industry, focusing on the manufacture, marketing, and distribution of hemp-derived supplements and cannabis products. They sell through e-commerce, retail, and hospitality channels under brands like Lord Jones and Happy Dance. The company cultivates, manufactures, and markets cannabis and cannabis-derived products for both medical and adult-use markets, primarily selling dried cannabis and pre-rolls.

Cronos Group Inc. is a cannabinoid company engaged in the cultivation, manufacture, and distribution of hemp-derived supplements and cannabis products for medical and adult-use markets. The company operates in the United States, Germany, Israel, and Australia, utilizing brands like Lord Jones, Happy Dance, PEACE NATURALS, and Spinach.

Key Facts

• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic
• Headquarters: Stayner, ON, CA
• CEO: Michael Ryan Gorenstein
• Employees: 459

What Cronos Group Inc. Does

Cultivate cannabis for medical and adult-use markets.,Manufacture hemp-derived supplements and cosmetic products.,Market and distribute hemp-derived products under Lord Jones and Happy Dance brands in the U.S.,Sell medical cannabis and cannabis-derived products via PEACE NATURALS.,Operate adult-use cannabis sales under the Spinach brand.,Export dried cannabis and cannabis oils to Germany, Israel, and Australia.,Produce various cannabis products including dried cannabis, pre-rolls, edibles, concentrates, and extracts.

Business Model

Direct-to-consumer sales of hemp-derived products through e-commerce platforms.,Wholesale distribution of hemp-derived products to retail and hospitality partners in the U.S.,Wholesale distribution of medical and adult-use cannabis products to licensed retailers and distributors.,Direct-to-client sales of medical cannabis through its PEACE NATURALS platform.,International export sales of dried cannabis and cannabis oils to regulated markets.

CRON Investment Analysis

Investment Thesis

Cronos Group Inc. operates in the evolving global cannabinoid market, positioning itself with a dual focus on hemp-derived wellness products in the U.S. and medical/adult-use cannabis internationally. The company's diversified brand portfolio, including Lord Jones, Happy Dance, PEACE NATURALS, and Spinach, allows it to address various consumer segments and regulatory environments. With a gross margin of 39.6%, Cronos demonstrates efficiency in its production and distribution, which is crucial in a competitive industry. Its low debt-to-equity ratio of 0.12 indicates a conservative financial structure, providing flexibility for future growth initiatives. While currently operating with a profit margin of -1.1% and a modest ROE of 0.5%, the investment thesis hinges on the potential for market expansion in both existing and new geographies, particularly as regulatory landscapes for cannabis continue to evolve. The company's ongoing international export activities to Germany, Israel, and Australia represent a key catalyst for revenue growth, leveraging established distribution channels. Furthermore, continued product innovation within its brand portfolio, especially in high-margin segments like edibles and concentrates, could drive improved profitability and market share in the upcoming years.

Growth Catalysts

• Upcoming: Potential for further international market expansion as more countries legalize or liberalize cannabis regulations, particularly in Europe and Asia-Pacific, creating new export opportunities for Cronos Group's products.
• Ongoing: Continued product innovation and diversification within the Spinach and PEACE NATURALS brands, including the introduction of new edibles, concentrates, and specialized medical formulations, which could capture higher market share and improve margins.
• Ongoing: Growth in the U.S. hemp-derived wellness market, driven by increasing consumer awareness and acceptance of products under the Lord Jones and Happy Dance brands, potentially expanding distribution channels and sales volumes.
• Upcoming: Strategic partnerships or acquisitions that could enhance Cronos Group's technological capabilities, expand its cultivation capacity, or provide access to new distribution networks in key growth markets.

Risk Factors

• Potential: Adverse changes in regulatory frameworks for cannabis and hemp, including re-criminalization, increased taxation, or stricter product standards, could significantly impact Cronos Group's operations and profitability.
• Ongoing: Intense competition within the global cannabinoid market from both established players and new entrants, potentially leading to price compression, reduced market share, and increased marketing expenditures.
• Potential: Supply chain disruptions, including issues with cultivation, processing, or logistics, could affect product availability and increase operational costs, impacting gross margins.
• Ongoing: Fluctuations in consumer demand and preferences for cannabinoid products, which could necessitate significant investment in research and development or marketing to adapt to changing market trends.

Questions & Answers

Is CRON a good stock to buy?

Whether CRON is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate Cronos Group Inc.'s revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice—consult a qualified advisor before investing.

What is the CRON MoonshotScore?

The MoonshotScore rates CRON from 0 to 100 across growth potential, financial health, market momentum, and risk factors. It is updated as market data refreshes. This score is informational only—not a buy or sell recommendation.

How often is CRON data updated?

CRON's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update as market data refreshes.

What are the risks of investing in CRON?

Risk categories for CRON include market risk, company-specific risk, financial risk (debt, cash burn), and macroeconomic risk. Review the Risk Factors section for details specific to this stock. All investments carry risk of loss.